Publications by authors named "Diana Gruenstein"

4 Publications

  • Page 1 of 1

Erythrasma in 4 skin of color patients with hidradenitis suppurativa.

JAAD Case Rep 2021 Jul 2;13:127-129. Epub 2021 Jun 2.

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2021.05.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226396PMC
July 2021

Trichotillomania due to pica in a 23-month-old patient with concomitant iron deficiency anemia and lead poisoning.

JAAD Case Rep 2021 Jan 19;7:91-92. Epub 2020 Nov 19.

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.11.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750178PMC
January 2021

Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab.

JAAD Case Rep 2020 Dec 15;6(12):1286-1287. Epub 2020 Oct 15.

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.10.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701016PMC
December 2020

A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature.

Acta Haematol 2019 7;142(2):105-112. Epub 2019 May 7.

Departments of Medicine and Pathology, Tumor Cytogenomics, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA,

The JAK2V617F point mutation has been implicated in the pathogenesis of the vast majority of myeloproliferative neoplasms (MPNs), but translocations involving JAK2 have increasingly been identified in patients with JAK2V617F-negativeMPNs. Here, we present a case of a patient diagnosed with JAK2V617F-negativepolycythemia vera (PV) that transformed to the MPN-blast phase. Cytogenetic and FISH analysis revealed a novel translocation of t(1;9)(p36;p24.1), causing a PEX14-JAK2 gene fusion product. The t(1;9)(p36;p24.1) represents a new addition to the list of known translocations involving JAK2that have been identified in hematologic malignancies. Although the prognostic and treatment implications of JAK2 translocations in MPNs have not been elucidated, positive outcomes have been described in case reports describing the use of JAK inhibitors in these patients. Further research into the role of JAK2 translocations in the pathogenesis and outcomes of hematologic malignancies is warranted.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1159/000498945DOI Listing
February 2020
-->